IP Library Granted Patent US 8,039,629
Granted Patent B2
US 8,039,629 · App. 11/793,482 · Granted Oct 18, 2011

Chemical compound and its use

Assignee: Bayer Pharma Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,039,629
App. No.
11/793,482
Granted
Oct 18, 2011
Kind
B2
Abstract

The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.

Claims (40)

1. A compound of the formula (I)

in which R represents cyclopentyl or isopropyl, or a salt thereof.

2. A compound of the formula (Ia)

or a salt thereof.

3. A compound of the formula (Ib)

or a salt thereof.

4. A pharmaceutical composition comprising the compound of the formula (I) as defined in any of claims 1 to 3 in combination with an inert nontoxic pharmaceutically suitable auxiliary.

5. A pharmaceutical composition comprising the compound of the formula (I) as defined in any of claims 1 to 3 in combination with one or more further active compounds selected from the group consisting of antidiabetics, platelet aggregation inhibitors, anticoagulants, calcium antagonists, angiotensin AII antagonists, ACE inhibitors, beta blockers, phosphodiesterase inhibitors, stimulators of soluble guanylate cyclase, cGMP enhancers, diuretics, thyroid receptor agonists, HMG-CoA reductase inhibitors, squalene synthase inhibitors, squalene epoxidase inhibitors, oxidosqualene cyclase inhibitors, ACAT inhibitors, MTP inhibitors, PPAR agonists, fibrates, lipase inhibitors, cholesterol absorption inhibitors, bile acid reabsorption inhibitors, polymeric bile acid adsorbers and lipoprotein(a) antagonists.

6. A process for preparing the compound of the formula (Ia) as defined in claim 2 , characterized in that the compound of the formula (IIa)

is initially, by asymmetric reduction, converted into the compound of the formula (IIIa)

which is then either

[A] by introduction of a hydroxyl protective group reacted to give a compound of the formula (IVa)

in which

PG represents a hydroxyl protective group,

and then, by diastereoselective reduction, converted into a compound of the formula (Va)

in which PG is as defined above,

or

[B] initially reduced diastereoselectively to give the compound of the formula (VIa)

which is then, by regioselective introduction of the hydroxyl protective group PG, converted into a compound of the formula (Va),

the compound of the formula (Va) is then, using a fluorinating agent, reacted to give a compound of the formula (VIIa)

in which PG is as defined above,

and the hydroxyl protective group PG is then cleaved off giving the compound of the formula (Ia)

and the compound of the formula (Ia) is optionally converted into a salt thereof.

7. A process for preparing the compound of the formula (Ib) as defined in claim 3 , characterized in that the compound of the formula (IIb)

is initially, by asymmetric reduction, converted into the compound of the formula (IIIb)

which is then either

[A] by introduction of a hydroxyl protective group reacted to give a compound of the formula (IVb)

in which

PG represents a hydroxyl protective group,

and then, by diastereoselective reduction, converted into a compound of the formula (Vb)

in which PG is as defined above,

or

[B] initially reduced diastereoselectively to give the compound of the formula (VIb)

which is then, by regioselective introduction of the hydroxyl protective group PG, converted into a compound of the formula (Vb),

the compound of the formula (Vb) is then, using a fluorinating agent, reacted to give a compound of the formula (VIIb)

in which PG is as defined above,

and the hydroxyl protective group PG is then cleaved off giving the compound of the formula (Ib)

and the compound of the formula (Ib) is optionally converted into a salt thereof.

8. The process of claim 6 , wherein PG is a radical of the formula —SiR 1 R 2 R 3 , in which R 1 , R 2 and R 3 are identical or different and represent (C 1 -C 4 ) alkyl.

9. The process of claim 7 , wherein PG is a radical of the formula —SiR 1 R 2 R 3 , in which R 1 , R 2 and R 3 are identical or different and represent (C 1 -C 4 ) alkyl.

Assignments (3)
CHANGE OF NAME Recorded Sep 19, 2011
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 026930/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2008
From: WOLTERING, ELISABETH; TUCH, AROUNARITH; DITTRICH-WENGENROTH, ELKE; KRETSCHMER, AXEL; BARFACKER, LARS; BAUSER, MARCUS; ELLINGHAUS, PETER; LUSTIG, KLEMENS; POOK, ELISABETH; WEBER, OLAF
To: BAYER HEALTHCARE AG
Reel/Frame 020628/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2008
From: BISCHOFF, HILMAR; GIELEN-HAERTWIG, HEIKE; LI, VOLKHART; SCHMECK, CARSTEN; THUTEWOHL, MICHAEL; VAKALOPOULOS, ALEXANDROS; WEBER, OLAF; WUTTKE, MARTINA
To: BAYER HEALTHCARE AG
Reel/Frame 020476/0374 →
Priority Claims (2)
DE 10 2004 060 997 · Dec 18, 2004 · national
DE 10 2004 061 000 · Dec 18, 2004 · national
Continuity (1)
Related Publication 20080255068A1 · Oct 16, 2008